Gastric cancer
E Van Cutsem, X Sagaert, B Topal, K Haustermans… - The Lancet, 2016 - thelancet.com
Gastric cancer is one of the leading causes of cancer-related death worldwide. Many
patients have inoperable disease at diagnosis or have recurrent disease after resection with …
patients have inoperable disease at diagnosis or have recurrent disease after resection with …
Metaplasia: tissue injury adaptation and a precursor to the dysplasia–cancer sequence
V Giroux, AK Rustgi - Nature Reviews Cancer, 2017 - nature.com
Metaplasia is the replacement of one differentiated somatic cell type with another
differentiated somatic cell type in the same tissue. Typically, metaplasia is triggered by …
differentiated somatic cell type in the same tissue. Typically, metaplasia is triggered by …
Diagnostic methods for Helicobacter pylori infection: ideals, options, and limitations
P Sabbagh, M Mohammadnia-Afrouzi… - European Journal of …, 2019 - Springer
Helicobacter pylori (H. pylori) resides in the stomach, colonizes gastric epithelium, and
causes several digestive system diseases. Several diagnostic methods utilizing invasive or …
causes several digestive system diseases. Several diagnostic methods utilizing invasive or …
Helicobacter pylori and Gastric Cancer: Adaptive Cellular Mechanisms Involved in Disease Progression
Helicobacter pylori (H. pylori) infection is the major risk factor associated with the
development of gastric cancer. The transition from normal mucosa to non-atrophic gastritis …
development of gastric cancer. The transition from normal mucosa to non-atrophic gastritis …
Chemotherapy for advanced gastric cancer
AD Wagner, NLX Syn, M Moehler… - Cochrane database …, 2017 - cochranelibrary.com
Background Gastric cancer is the fifth most common cancer worldwide. In" Western"
countries, most people are either diagnosed at an advanced stage, or develop a relapse …
countries, most people are either diagnosed at an advanced stage, or develop a relapse …
Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial
SJ Dutton, DR Ferry, JM Blazeby, H Abbas… - The lancet …, 2014 - thelancet.com
Background Evidence is scarce for the effectiveness of therapies for oesophageal cancer
progressing after chemotherapy, and no randomised trials have been reported. We aimed to …
progressing after chemotherapy, and no randomised trials have been reported. We aimed to …
lncRNA GAS5 enhances G1 cell cycle arrest via binding to YBX1 to regulate p21 expression in stomach cancer
Y Liu, J Zhao, W Zhang, J Gan, C Hu, G Huang… - Scientific reports, 2015 - nature.com
Long non-coding RNAs (lncRNAs), which have evolved as important gene expression
modulators, are involved in human malignancies. The down-regulation of lncRNA growth …
modulators, are involved in human malignancies. The down-regulation of lncRNA growth …
Cancer-associated fibroblasts promote aggressive gastric cancer phenotypes via heat shock factor 1–mediated secretion of extracellular vesicles
N Grunberg, M Pevsner-Fischer, T Goshen-Lago… - Cancer research, 2021 - AACR
Gastric cancer is the third most lethal cancer worldwide, and evaluation of the genomic
status of gastric cancer cells has not translated into effective prognostic or therapeutic …
status of gastric cancer cells has not translated into effective prognostic or therapeutic …
Characterization of the prognostic m6A-related lncRNA signature in gastric cancer
H Wang, Q Meng, B Ma - Frontiers in oncology, 2021 - frontiersin.org
N6-methyladenosine (m6A) is a common form of mRNA modification regulated by m6A RNA
methylation regulators and play an important role in the progression of gastric cancer (GC) …
methylation regulators and play an important role in the progression of gastric cancer (GC) …
Apatinib: a novel receptor tyrosine kinase inhibitor for the treatment of gastric cancer
Metastatic gastric cancer is a lethal disease characterized by a very short overall survival,
underlining a critical need of new therapeutic options. Unfortunately, although several …
underlining a critical need of new therapeutic options. Unfortunately, although several …